Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 628,073
  • Shares Outstanding, K 119,633
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,200 K
  • EBIT $ -219 M
  • EBITDA $ -216 M
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.60

Options Overview Details

View History
  • Implied Volatility 101.50% (-1.20%)
  • Historical Volatility 65.67%
  • IV Percentile 11%
  • IV Rank 8.16%
  • IV High 553.56% on 04/16/25
  • IV Low 61.35% on 01/13/25
  • Expected Move (DTE 5) 0.67 (12.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 139
  • Volume Avg (30-Day) 542
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 23,180
  • Open Int (30-Day) 21,168
  • Expected Range 4.58 to 5.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.36
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.55 +15.51%
on 01/05/26
5.73 -8.38%
on 01/07/26
+0.39 (+8.02%)
since 12/09/25
3-Month
2.54 +106.69%
on 11/13/25
5.73 -8.38%
on 01/07/26
+1.99 (+61.04%)
since 10/09/25
52-Week
1.28 +310.16%
on 04/10/25
5.73 -8.38%
on 01/07/26
+0.41 (+8.47%)
since 01/08/25

Most Recent Stories

More News
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan....

ANNX : 5.25 (-0.76%)
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.25 (-0.76%)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 5.25 (-0.76%)
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 5.25 (-0.76%)
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 5.25 (-0.76%)
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing...

ANNX : 5.25 (-0.76%)
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in  Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA...

ANNX : 5.25 (-0.76%)
Annexon Biosciences to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...

ANNX : 5.25 (-0.76%)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...

ANNX : 5.25 (-0.76%)
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability...

ANNX : 5.25 (-0.76%)

Business Summary

Annexon Inc. is a clinical-stage biopharmaceutical company. It engages in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's product candidate includes ANX005 and ANX007, which are in clinical stage. Annexon Inc....

See More

Key Turning Points

3rd Resistance Point 5.77
2nd Resistance Point 5.66
1st Resistance Point 5.45
Last Price 5.25
1st Support Level 5.13
2nd Support Level 5.02
3rd Support Level 4.81

See More

52-Week High 5.73
Last Price 5.25
Fibonacci 61.8% 4.03
Fibonacci 50% 3.51
Fibonacci 38.2% 2.98
52-Week Low 1.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar